1. Home
  2. THFF vs OMER Comparison

THFF vs OMER Comparison

Compare THFF & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Financial Corporation Indiana

THFF

First Financial Corporation Indiana

N/A

Current Price

$79.41

Market Cap

940.1M

Sector

Finance

ML Signal

N/A

Logo Omeros Corporation

OMER

Omeros Corporation

HOLD

Current Price

$19.35

Market Cap

844.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
THFF
OMER
Founded
1984
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
940.1M
844.6M
IPO Year
1995
2008

Fundamental Metrics

Financial Performance
Metric
THFF
OMER
Price
$79.41
$19.35
Analyst Decision
Hold
Strong Buy
Analyst Count
2
5
Target Price
$62.00
$32.50
AVG Volume (30 Days)
77.8K
2.4M
Earning Date
04-28-2026
05-14-2026
Dividend Yield
3.46%
N/A
EPS Growth
67.00
98.15
EPS
3.58
0.77
Revenue
N/A
$29,868,000.00
Revenue This Year
$17.88
N/A
Revenue Next Year
$4.03
$233.22
P/E Ratio
$22.24
$25.09
Revenue Growth
N/A
N/A
52 Week Low
$51.21
$3.94
52 Week High
$84.17
$19.58

Technical Indicators

Market Signals
Indicator
THFF
OMER
Relative Strength Index (RSI) 53.52 86.30
Support Level $79.72 $9.12
Resistance Level $84.00 N/A
Average True Range (ATR) 1.68 0.84
MACD -0.47 0.41
Stochastic Oscillator 37.70 96.99

Price Performance

Historical Comparison
THFF
OMER

About THFF First Financial Corporation Indiana

First Financial Corp operates as a financial holding company, which is engaged in the provision of financial services in the United States. The company offers a wide variety of financial services including commercial, mortgage, and consumer lending, lease financing, trust account services, depositor services and insurance services, through its subsidiaries. Its primary source of revenue is derived from loans to customers and investment activities. Company's loan portfolio was diversified in Commercial, Residential and consumer domains.

About OMER Omeros Corporation

Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.

Share on Social Networks: